Principal Financial Group Inc Abb Vie Inc. Transaction History

Principal Financial Group Inc

$1.66 Trillion
Q3 2024

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$163.84 - $199.33 $44.7 Million - $54.4 Million	273,078 Added 12.33%	2,487,363 $491 Million
Q2 2024 Jul 29, 2024	SELL	$154.79 - $180.76 $6.17 Million - $7.21 Million	-39,892 Reduced 1.77%	2,214,285 $380 Million
Q1 2024 Apr 29, 2024	SELL	$159.82 - $182.1 $5.29 Million - $6.03 Million	-33,121 Reduced 1.45%	2,254,177 $410 Million
Q4 2023 Feb 07, 2024	BUY	$137.6 - $154.97 $3.3 Million - $3.72 Million	23,991 Added 1.06%	2,287,298 $354 Million
Q3 2023 Nov 02, 2023	SELL	$133.59 - $154.65 $2.36 Million - $2.74 Million	-17,692 Reduced 0.78%	2,263,307 $337 Million
Q2 2023 Aug 07, 2023	SELL	$132.51 - $164.9 $10.9 Million - $13.5 Million	-81,998 Reduced 3.47%	2,280,999 $307 Million
Q1 2023 May 09, 2023	BUY	$144.61 - $166.54 $1.79 Million - $2.07 Million	12,409 Added 0.53%	2,362,997 $377 Million
Q4 2022 Feb 09, 2023	BUY	$138.31 - $165.87 $4.12 Million - $4.94 Million	29,779 Added 1.28%	2,350,588 $380 Million
Q3 2022 Nov 09, 2022	SELL	$134.21 - $153.93 $13.2 Million - $15.2 Million	-98,703 Reduced 4.08%	2,320,809 $311 Million
Q2 2022 Aug 10, 2022	SELL	$137.62 - $174.96 $8.94 Million - $11.4 Million	-64,974 Reduced 2.62%	2,419,512 $371 Million
Q1 2022 May 09, 2022	SELL	$131.98 - $163.75 $3.58 Million - $4.44 Million	-27,139 Reduced 1.08%	2,484,486 $403 Million
Q4 2021 Feb 09, 2022	SELL	$107.43 - $135.93 $7.11 Million - $8.99 Million	-66,165 Reduced 2.57%	2,511,625 $340 Million
Q3 2021 Nov 09, 2021	SELL	$106.4 - $120.78 $7.52 Million - $8.54 Million	-70,716 Reduced 2.67%	2,577,790 $278 Million
Q2 2021 Aug 10, 2021	SELL	$105.21 - $117.21 $3.1 Million - $3.46 Million	-29,499 Reduced 1.1%	2,648,506 $298 Million
Q1 2021 May 10, 2021	SELL	$102.3 - $112.62 $18.2 Million - $20.1 Million	-178,098 Reduced 6.24%	2,678,005 $290 Million
Q4 2020 Feb 23, 2021	SELL	$80.49 - $108.67 $91.4 Million - $123 Million	-1,135,356 Reduced 28.44%	2,856,103 $306 Million
Q4 2020 Feb 08, 2021	BUY	$80.49 - $108.67 $118 Million - $159 Million	1,465,208 Added 58.0%	3,991,459 $428 Million
Q3 2020 Nov 06, 2020	SELL	$85.91 - $100.83 $16.1 Million - $18.9 Million	-187,440 Reduced 6.91%	2,526,251 $221 Million
Q2 2020 Aug 05, 2020	BUY	$73.37 - $98.18 $41 Million - $54.8 Million	558,412 Added 25.91%	2,713,691 $266 Million
Q1 2020 May 12, 2020	SELL	$64.5 - $97.79 $560,376 - $849,599	-8,688 Reduced 0.4%	2,155,279 $164 Million
Q4 2019 Feb 05, 2020	SELL	$72.13 - $90.25 $16.6 Million - $20.7 Million	-229,604 Reduced 9.59%	2,163,967 $192 Million
Q3 2019 Nov 13, 2019	SELL	$62.98 - $75.72 $2.46 Million - $2.96 Million	-39,108 Reduced 1.61%	2,393,571 $181 Million
Q2 2019 Aug 12, 2019	BUY	$65.7 - $83.98 $4.86 Million - $6.21 Million	73,929 Added 3.13%	2,432,679 $177 Million
Q1 2019 May 10, 2019	SELL	$77.14 - $90.79 $3.8 Million - $4.47 Million	-49,248 Reduced 2.05%	2,358,750 $190 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $21.2 Million - $26.2 Million	-272,938 Reduced 10.18%	2,407,998 $222 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $61,614 - $68,496	693 Added 0.03%	2,680,936 $254 Million
Q2 2018 Aug 13, 2018	SELL	$89.78 - $106.23 $19.8 Million - $23.5 Million	-221,062 Reduced 7.62%	2,680,243 $0
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $5.65 Million - $7.56 Million	-61,380 Reduced 2.07%	2,901,305 $275 Million
Q4 2017 Feb 13, 2018	SELL	$89.56 - $98.21 $31.1 Million - $34.1 Million	-346,721 Reduced 10.48%	2,962,685 $287 Million
Q3 2017 Nov 02, 2017	BUY	$69.85 - $89.22 $231 Million - $295 Million	3,309,406	3,309,406 $294 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account